Both c-Jun N-terminal kinase (JNK) and reactive oxygen species (ROS) play important roles in myocardial ischemia/reperfusion (I/R) injury. Our previous studies suggest that N-n-butyl haloperidol iodide ($F_2$) exerts cardioprotection by reducing ROS production and JNK activation caused by I/R. In this study, we hypothesized that there is a JNK/Sab/Src/ROS pathway in the mitochondria in H9c2 cells following hypoxia/reoxygenation (H/R) that induces oxidative stress in the mitochondria and that $F_2$ exerts mitochondrial protective effects during H/R injury by modulating this pathway. The results showed that H/R induced higher-level ROS in the cytoplasm on the one hand and JNK activation and translocation to the mitochondria by colocalization with Sab on the other. Moreover, H/R resulted in mitochondrial Src dephosphorylation, and subsequently, oxidative stress evidenced by the increase in ROS generation and oxidized cardiolipin in the mitochondrial membranes and by the decrease in mitochondrial superoxide dismutase activity and membrane potential. Furthermore, treatment with a JNK inhibitor or Sab small interfering RNA inhibited the mitochondrial translocation of p-JNK, decreased colocalization of p-JNK and Sab on the mitochondria, and reduced Src dephosphorylation and mitochondrial oxidative stress during H/R. In addition, Src dephosphorylation by inhibitor PP2 increased mitochondrial ROS production. $F_2$, like inhibitors of the JNK/Sab/Src/ROS pathway, downregulated the H/R-induced mitochondrial translocation of p-JNK and the colocalization of p-JNK and Sab on the mitochondria, increased Src phosphorylation, and alleviated the above-mentioned mitochondrial oxidative stress. In conclusion, $F_2$ could ameliorate H/R-associated oxidative stress in mitochondria in H9c2 cells through the mitochondrial JNK/Sab/Src/ROS pathway.
1. Introduction

Ischemia/reperfusion (I/R) injury refers to an increase in organic damage that occurs with the restoration of blood flow after ischemia. Myocardial I/R injury is considered a major health threat and is associated with acute coronary syndromes. Timely coronary revascularization has become a routine treatment approach for patients with significant ST-segment elevation, but reperfusion of blood into the previous ischemic area is always accompanied by increased myocardial injury. Studies have shown that a small amount of reactive oxygen species (ROS) has cardioprotective effects [1]. For example, redox signaling derived from ROS is responsible for cardiomyocyte differentiation and excitation-contraction coupling [2]. Wu et al. [3] also demonstrated that during early reperfusion, the moderate ROS plays an important role in the intermittent hypobaric hypoxia-avoided cardioprotection by activating the JAK2/STAT3 pathway against I/R-induced Ca^{2+} overload and contractile dysfunction. On the contrary, a large number of studies have shown that overgenerated ROS play a vital role in the pathological process of myocardial I/R injury, which not only induces oxidative stress injury but also participates in other I/R-associated damages [4]. As our previous studies show, ROS accumulation leads to oxidation of the lipid structure of the cell membrane, increases cell membrane permeability, and subsequently causes the leakages of CK, LDH, and cTnI from cardiomyocyte [5, 6] in hypoxia/reoxygenation (H/R). Overproduced ROS during I/R is responsible for the damage of mitochondrial DNA [7], protein oxidation [8], inflammation [9], apoptosis [10], and necrosis. However, the specific pathogenesis about the relationship between ROS and myocardial I/R injury remains obscure.

The mitochondrion is an important organelle that is responsible for ROS production, oxidative phosphorylation, energy metabolism, and maintenance of calcium homeostasis. In previous studies, mitochondria have been shown to be the main site of ROS generation and a key target for cardiac protection strategies during reperfusion. Mitochondrial ROS are derived from mitochondrial respiratory chain and ROS production enzymes. When the myocardium suffers from I/R, a burst of ROS generated from the mitochondria will trigger mitochondrial permeability transition pore opening, decrease myocardial contractile function, induce arrhythmia, and prompt myocardial apoptosis or necrosis.

The c-Jun N-terminal kinase (JNK) (known as stress-activated protein kinases) is a key modulator in cell death mediated by ROS [11]. In our previous work, we found that ROS can promote the phosphorylation of JNK in the cytoplasm and cause H/R injury when cardiac microvascular endothelial cells and H9c2 cells are subjected to H/R [5, 12]. Proto-oncogene tyrosine-protein kinase Src (c-Src) was the first tyrosine kinase to be identified [13, 14]. In a mechanism study of ischemic preconditioning, Ge et al. found that mitochondrial Src protein regulates the mitochondrial complex I activity and regulates mitochondrial ROS production to protect the myocardium from I/R injury [15]. Recently, Win et al. [16] found that activated JNK could bind to the mitochondrial outer membrane SH3 domain-binding protein 5 (SH3BP5 or Sab), leading to SHP1 protein bind to Sab protein release to the mitochondrial inner membrane, which ultimately resulted in SHP1-dependent inactivation of p-Src in liver injury models. Chambers et al. [17] have also reported that H_{2}O_{2}/iron sulfate (FeSO_{4}) can activate JNK signaling and cause it to translocate to the mitochondria via Sab in H9c2 cells. Taken together, we speculated that a JNK/Sab/Src/ROS signaling pathway triggered by cytoplasmic ROS may exist in mitochondria during myocardial I/R and that this "ROS-induced ROS release" will at first give rise to mitochondrial oxidative stress and then to whole-cell oxidative stress.

N-n-Butyl haloperidol iodide (F_{2}) (Chinese national invention patent no. ZL96119098.1) synthesized by our laboratory is a new type of calcium antagonist derived from haloperidol, which is used to treat psychological diseases. Previous studies have confirmed that F_{2} could protect cardiomyocytes from I/R injury in vivo or H/R injury in vitro. The mechanism of F_{2} may be related to blocking of the cell membrane Ca^{2+} channel and the inhibition of Egr-1 overexpression, which has been well documented to be closely associated with I/R-mediated inflammation [6, 18, 19]. It also has been found that F_{2} can improve intracellular oxidative stress [5, 12], such as decreasing the level of ROS, increasing the activity of superoxide dismutase (SOD), and reducing the content of malonaldehyde (MDA). Moreover, studies have demonstrated that F_{2} inhibits cytoplasmic JNK activation in cardiomyocytes during H/R and that cytoplasmic ROS mediates the process.

In this study, we constructed an H/R injury model of H9c2 cells by using a hypoxia/anaerobic workstation to simulate myocardial I/R injury and observed whether a JNK/Sab/Src/ROS signaling pathway was present in the mitochondria and could trigger mitochondrial oxidative stress. On the basis of this, we aimed to investigate whether F_{2} ameliorates mitochondrial oxidative stress injury during H/R by regulating the above pathway.

2. Materials and Methods

2.1. Reagent Preparation. The H9c2 cell line was from the American Type Culture Collection (ATCC, Rockville, MD, USA). F_{2} was synthesized by our laboratory (Chinese national invention patent no. ZL96119098.1). Dulbecco’s modified Eagle’s medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco Laboratories (Carlsbad, CA, USA). The JNK inhibitor SP600125 was from Enzo Life Sciences (Farmingdale, NY, USA). The JNK activator anisomycin and 2,7′-dichlorofluorescein acetyl acetate were obtained from Sigma-Aldrich (St. Louis, MO, USA). Small interfering ribonucleic acids (siRNAs) were purchased from Shanghai GenePharma Co. Ltd. (Suzhou, China). The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium (MTT) reagent was gathered from Amresco (Solon, OH, USA). A Pierce ™ Bicinchoninic Acid Assay Kit and SuperSignal detection kit were obtained from Thermo-Fisher.
Scientific (Waltham, MA, USA), as were Alexa Fluor™ 594-conjugated anti-mouse secondary antibody, Alexa Fluor™ 488-conjugated anti-rabbit antibody, and mitochondrial-selective dye MitoSOX™ Red.

The primary antibodies used for Western blot analysis in this study were as follows: p-JNK (no. 4668), JNK (no. 29252), p-Src (Tyr416) (no. 6943), c-Src (no. 2109), and COX-IV (no. 4850) (Cell Signaling Technology, Danvers, MA, USA); Sab (H00009467-M01 from Novus Biologicals, Littleton, CO, USA); and β-actin (no. 66009-1-lg from the Proteintech Group, Chicago, IL, USA). The secondary antibody against β-actin, anti-rabbit, and anti-mouse were purchased from Wuhan Boster Bio-Engineering Ltd. Co. (Wuhan, China).

2.2. H9c2 Cell Culture and Hypoxia/Reoxygenation Protocol. H9c2 cells were cultured in DMEM supplemented with 10% FBS at 37°C under 5% CO2. To induce hypoxia stress, H9c2 cells were cultured in hypoxia buffer solution [20] (137 mM of sodium chloride, 12 mM of potassium chloride, 0.49 mM of magnesium chloride hexahydrate, 0.9 mM of calcium chloride, 4 mM of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, and 20 mM of sodium lactate, add hydrogen chloride to pH 6.2) and cultured in a hypoxia/anaerobic workstation (Ruskinn, England) (1% O2, 5% CO2, 94% N2, 37°C) for 1, 2, 4, 6, or 8 hours. Then, the hypoxia buffer solution was replaced with fresh culture medium containing 10% FBS, and the cells were transferred into a normoxic incubator for 1 hour of reoxygenation.

2.3. Sab Small Interfering RNA. The protocol of Sab small interfering RNA is similar to our previous study [21]. The cells were inoculated in 6-well cell culture dishes and transfected with Sab siRNA by Gibco™ Opti-MEM™ media (Thermo-Fisher Scientific, Waltham, MA, USA). In brief, 3 μl of 20 μM Sab siRNA-1, 3 μl of 20 μM Sab siRNA-2, and 4 μl of 20 μM Sab siRNA-3—that is, Sab siRNA-1: Sab siRNA-2: Sab siRNA-3 = 3:3:4—or 10 μl negative control (NC) siRNA were mixed with 250 μl of the Opti-MEM™ media, separately (the sequences of each siRNA and negative control were shown in Table 1). Next, Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) was mixed with the Opti-MEM™ media, and then, the mixtures were combined for 20 minutes at room temperature. Subsequently, H9c2 cells were incubated with mixture for 6 hours. At last, the medium was then changed into antibiotic-free DMEM supplemented with 10% FBS for 48 hours.

2.4. Experimental Groups. H9c2 cells were randomly allocated to the following groups: control, H/R, H/R+JNK inhibitor (H/R+SP600125), H/R+negative control siRNA (H/R +NC siRNA), H/R+Sab siRNA, control+Scrib inhibitor (control+PP2), H/R+F_2, and H/R+F_2+JNK agonist (H/R+F_2 +Aniso). The working concentration and the time of each group were as follows: the cultured solution of the control group is replaced with fresh DMEM before the experiment, and 20 μM SP600125 was preincubated for 45 minutes before H/R. NC siRNA or Sab siRNA sequence was transected into cells for 6 hours and then cultured with 10% FBS Opti-MEM™ medium for 48 hours. Also, 10 μM PP2 was preincubated for 12 hours under normoxic conditions, and 10 μM F_2 was added to cells during prehypoxia for 30 minutes and hypoxia for 2 hours. Additionally, 20ng/ml of Aniso was given to cells during hypoxia. The administration protocol was presented in Figure 1.

2.5. Cell Viability Assay. The viability of H9c2 cells was assessed by the MTT reagent according to the manufacturer’s instructions [22]. H9c2 cells (5 x 10^3) were seeded in 96-well plates for 48 hours and then subjected to hypoxia for 0, 1, 2, 4, 6, and 8 hours and reoxygenation for 1 hour. After the above treatment, 5 mg/ml MTT was added to the medium in each well, and the cells were incubated for 4 hours at 37°C with shielding from light. The medium was subsequently replaced with 150 μl of dimethyl sulfoxide to solubilize the formazan. The absorbance was detected by a microplate reader (SpectraMax, Molecular Devices, Sunnyvale, CA, USA) at 490 nm.

2.6. Mitochondrial Isolation. Mitochondria were isolated by the method described by Wu et al. [23]. After the different treatments as indicated, the H9c2 cells were harvested. The mitochondria were isolated by using a mitochondria isolation kit. Briefly, cells were incubated in 500 μl of the mitochondrial separation reagent containing 1 mM of phenylmethylsulfonyl fluoride and 1 mM of sodium orthovanadate for 15 minutes on ice and then were taken into a glass homogenizer and homogenized for 20 up-down strokes using a tight pestle on ice. The homogenate was separated by centrifugation at 1,000 g for 10 minutes at 4°C. The supernatant was collected and centrifuged again at 11,000 g for 15 minutes at 4°C to obtain the cytosolic (supernatant) and mitochondrial (deposition) fractions. Then, 76 μl of mitochondrial lysis buffer was added into the isolated mitochondria. Finally, the protein concentration was measured by the bicinchoninic acid assay kit. Mitochondria were then homogenized for Western blot.

2.7. Western Blot Analysis. The protocol of extracting cells is as previously described [5, 20]. The equal denatured protein underwent 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and then was transferred to a nitrocellulose membrane by electrophoresis. Membranes were blocked with 5% fat-free milk and immunobblotted with diluted primary antibody: anti-phospho-JNK (1:400), anti-Sab (1:250), anti-p-Src (1:250), anti-c-Src (1:1000), anti-COX-IV (1:400), and anti-β-actin (1:5000) and then incubated at 4°C overnight, which was followed by exposure to horseradish peroxidase-conjugated secondary antibodies (typically 1:20,000 dilution) for 1 hour at room temperature. Transferred proteins were visualized by use of a SuperSignal detection kit (Thermo-Fisher Scientific, Waltham, MA, USA). The bands were analyzed with the Gel-Pro Image Analysis Software (Media Cybernetics, USA). The level of each mitochondrial protein was expressed as its density to the density of mitochondrial loading control COX-IV. To avoid the error in different batches, the desity ratio
between interest protein and COX-IV in the H/R group was set as 1.

2.8. Immunoﬂuorescent Detection of Colocalization of Phospho-JNK and Sab. H9c2 cells were seeded at glass coverslips placed in a 24-well dish. After being treated according to the different group protocols, the coverslips were washed with cold phosphate-buffered saline (PBS) and placed in 4% paraformaldehyde for 20 minutes at room temperature. After being permeabilized with 0.1% Triton X-100, the cells were blocked with goat serum for 1 hour at room temperature. The process described above is similar to our previous study [21]. Next, the cells were incubated with primary rabbit anti-phospho-JNK (1 : 50) and mouse anti-Sab (1 : 50) antibodies overnight at 4°C. Sab was detected using an Alexa Fluor™ 594-conjugated anti-mouse secondary antibody (Thermo-Fisher Scientiﬁc, Waltham, MA, USA), while phospho-JNK was detected using an Alexa Fluor™ 488-conjugated anti-rabbit antibody (Thermo-Fisher Scientiﬁc, Waltham, MA, USA). Finally, the cover glasses were mounted on a glass slide, and images were observed with a confocal laser scanning microscope (Carl Zeiss AG, Oberkochen, Germany).

Negative control  | Sense | Antisense |
|-----------------|-------|-----------|
| Rat-Sh3bp5-siRNA-1  | Sense | 5′- GAAUGUCUGAAUCCACGUdTdT -3′ |
|                  | Antisense | 5′- UAGCGUGAUAAGCUUUGdTdT -3′ |
| Rat-Sh3bp5-siRNA-2  | Sense | 5′- GUUAAUCAUCCACGUdTdT -3′ |
|                  | Antisense | 5′- AUCGGUGAUAAGCUUUGdTdT -3′ |
| Rat-Sh3bp5-siRNA-3  | Sense | 5′- GGAUCUGGAGAUAACGdTdT -3′ |
|                  | Antisense | 5′- UGAUCUGAUAAGCUUUGdTdT -3′ |

Table 1: siRNA duplexes.

Figure 1: The protocol of experimental grouping and treatments: (a) protocol used in investigating whether the mitochondrial JNK/Sab/Src/ROS signaling pathway is activated in H9c2 cells after H/R and (b) protocol used in investigating the role of F2 in H9c2 cells after H/R.

2.9. Detection of Mitochondrial Superoxide. Mitochondrial superoxide production in H9c2 cells was detected with the mitochondria-selective dye MitoSOX™ Red (Thermo-Fisher Scientiﬁc, Waltham, MA, USA) [24] by using ﬂow cytometry or the confocal laser scanning microscope. Brieﬂy, cells were incubated with 5 μM of MitoSOX™ Red (Thermo-Fisher Scientiﬁc, Waltham, MA, USA) for 10 minutes at 37°C in the dark. Then, cells were washed three times with PBS and monitored with ﬂow cytometry at an excitation wavelength of 510 nm and an emission wavelength of 580 nm, and the image was recorded by the confocal laser scanning microscope and was analyzed by the Image-Pro Plus software (Media Cybernetics, US). The results were expressed as the ﬂuorescence ratio of each group to the control group. The mean ﬂuorescence intensity was analyzed using a BD Accuri™ C6 ﬂow cytometer (BD Biosciences, San Jose, CA, USA).

2.10. Measurement of the Mitochondrial Nonyl Acridine Orange Level. The concentration of mitochondrial cardiolipin was presented by using nonyl acridine orange (NAO) [25]. For assessment of mitochondrial membrane damage, cells were stained with 100 nM of "NAO" at 37°C for 30
minutes in the dark. The cells were washed with PBS and analyzed immediately using the BD Accuri™ C6 flow cytometer (BD Biosciences, San Jose, CA, USA).

2.11. Measurement of Mitochondrial Membrane Potential. Mitochondrial membrane potential was monitored using the JC-1 dye kit [26]. H9c2 cells were seeded in a petri dish.
After treatment, the cells were incubated with JC-1 for 20 minutes at 37°C in the dark, and images were taken with a fluorescence microscope (Olympus, Tokyo, Japan).

2.12. Manganese Superoxide Dismutase Activity. The activities of total SOD and copper and zinc SOD (CuZnSOD) in the H9c2 cells were measured by the colorimetric assay kit. The protocol used is as described in the manufacturer's instructions, and the details have been presented in our previous study [21]. Manganese SOD (MnSOD) activity = total SOD activity − CuZnSOD activity. All results were expressed as units per milligram of protein.

2.13. Statistical Analysis. The data are presented as mean ± standard error of the mean (SEM). Statistical significance was compared using one-way analysis of variance, followed by a Student–Newman–Keuls test, and P values less than 0.05 were considered to be statistically significant.

3. Results

3.1. Reactive Oxygen Species Levels and p-c-Jun N-Terminal Kinase Protein Expression in H9c2 Cell Cytoplasm and Cell Viability during Hypoxia/Reoxygenation over Time. To investigate the effects of different durations of H/R on the ROS level and p-JNK expression in H9c2 cell cytoplasm and cell viability, H9c2 cells were cultured in a hypoxia/anaerobic workstation for 1, 2, 4, 6, or 8 hours and then returned to normal conditions for 1 hour of reoxygenation. Flow cytometry analysis revealed that H/R time-dependently increased ROS levels (Figure 2(a)), with a significant difference beginning at 2 hours of hypoxia and 1 hour of reoxygenation (H: 2 hours/R: 1 hour), respectively. Exposure of H9c2 cells to H/R resulted in a significant decline in cell viability with a time dependence (Figure 2(b)). We assessed the time course for JNK and p-JNK. JNK protein expression did not change in H/R over time as was expected (Figure 2(c)). In contrast,
Figure 2(c) also shows H/R activated the phosphorylation of JNK as compared with the control group. In comparison with the control group, the ROS level, JNK activity, and cell viability all remarkably changed beginning at H: 2 hours/R: 1 hour. Based on the above data, H: 2 hours/R: 1 hour were used in subsequent experiments.

3.2. Effects of c-Jun N-Terminal Kinase on Sab Protein Expression and Src Activity and the Reactive Oxygen Species Level in Mitochondria in H9c2 Cells.

To determine the expression of p-JNK in mitochondria during H/R and the effects of p-JNK on mitochondrial Sab and Src, we isolated mitochondria from H9c2 cells after treatment. As shown in Figure 3(a), there was no p-JNK localized to the mitochondria in the control group, but, after H/R treatment, p-JNK was found in the mitochondria and p-Src expression decreased. When JNK inhibitor SP600125 was used before H/R, the level of mitochondrial p-JNK markedly decreased and Src dephosphorylation was reversed. At the same time, the differences of Sab expression were not significant among each group (Figure 3(a)). Under normal conditions, the mitochondrial ROS level is lower. However, after H/R treatment, the mitochondrial ROS level increased, whereas SP600125 could decrease the level of mitochondrial ROS (Figure 3(b)).

Figure 4: Sab mediates p-JNK translocation, Src activation, and mitochondrial ROS production in H9c2 cells subjected to H/R. (a) Sab, p-JNK, p-Src, c-Src, and COX-IV levels were analyzed by Western blot; n = 3. Data are expressed as the base of the levels of the H/R group. (b) The level of mitochondrial ROS was detected by the laser scanning confocal microscope; n = 3. Data are expressed as the base of the levels of the control group. All values are expressed as means ± SEMs. *P < 0.05 vs. control group; **P < 0.05 vs. H/R group; ▲P < 0.05 vs. H/R+NC siRNA (×400, bar = 20 μm).

3.3. Effects of Sab on p-c-Jun N-Terminal Kinase Protein Expression and Src Activity and the Reactive Oxygen Species Level in Mitochondria in H9c2 Cells. We assessed the Sab dependence of the effects of JNK on mitochondrial Src activity by knocking down Sab expression using Sab siRNA. Figure 4(a) shows that Sab siRNA successfully knocked down
Sab expression. When we blocked Sab, mitochondrial p-JNK translocation was inhibited and Src dephosphorylation was reversed (Figure 4(a)). During the whole process, c-Src expression did not exhibit any change as we expected. The high level of mitochondrial ROS caused by H/R was inhibited when we knocked down Sab protein (Figure 4(b)). Additionally, as can be seen, NC siRNA had no effect on the expression of protein and the level of mitochondrial ROS.

3.4. Effects of Src Activity on Mitochondrial Reactive Oxygen Species Levels in H9c2 Cells. To further clarify the role of Src, we used the Src classical inhibitor PP2 to inhibit Src phosphorylation and observed its effect on mitochondrial ROS production (Figure 5(a)). Flow cytometry analysis indicated that inhibiting Src phosphorylation increased mitochondrial ROS levels (Figure 5(b)).

3.5. N-n-Butyl Haloperidol Iodide Inhibits the Mitochondrial JNK/Sab/Src/ROS Pathway in H9c2 Cells Subjected to Hypoxia/Reoxygenation. Based on the above-mentioned findings, we confirmed that there was a JNK/Sab/Src/ROS pathway in the mitochondria of H9c2 cells subjected to H/R. Next, we sought to ascertain the role of F2 in this pathway. As compared with the control group, both p-JNK and ROS production increased in the mitochondria of the H/R group, while p-Src expression decreased in the mitochondria of the H/R group (Figures 6(a)–6(c)). F2 could possibly reverse the above-mentioned change (Figures 6(a)–6(c)). However, JNK agonist Aniso also abrogated the F2-induced decrease in p-JNK expression and F2-induced increase in p-Src in H9c2 cells following H/R (Figure 6(a)). Still, there were no significant differences in Sab protein expression among all groups. To further verify the effects of F2 on mitochondrial p-JNK in a Sab dependence, immunofluorescence colocalization was used to explore whether there was interaction between p-JNK protein (green) and Sab protein (red) in H9c2 cells subjected to H/R and what the effects of F2 on them were. As illustrated in Figure 6(c), obviously, in the control group, p-JNK (green) is little; Sab (red) was found on the outer mitochondrial membrane. The treatment of H/R induced p-JNK generation and bound to Sab protein (yellow), but F2 blocked this interaction. The results showed that H/R caused the translocation of p-JNK into mitochondria and that F2 could inhibit this process.

3.6. The Relationship between Mitochondrial Oxidative Stress and the JNK/Sab/Src/ROS Pathway and the Effects of N-n-Butyl Haloperidol Iodide on Them

3.6.1. Mitochondrial Membrane Potential. Via JC-1 staining, red fluorescence reflects higher mitochondrial membrane potential, and green fluorescence reflects lower mitochondrial membrane potential. As illustrated in Figure 7, red fluorescence was stronger in the control group, which indicated a higher mitochondrial membrane potential in normal conditions. As compared with the control group, the H/R group,
the H/R+NC siRNA group, and the control+PP2 group all had weaker red fluorescence and stronger green fluorescence, which indicated mitochondrial damage. However, the treatment of Sab siRNA, SP600125, and F₂ alleviated H/R-induced lower mitochondrial membrane potential. These findings suggest that inhibiting the JNK/Sab/Src pathway or using F₂ could increase mitochondrial membrane potential and ameliorate mitochondrial injury.

3.6.2. Manganese Superoxide Dismutase Activity. MnSOD activity was examined to assess the degree of mitochondrial antioxidative ability in H9c2 cells subjected to H/R. Figure 6: F₂ regulates the mitochondrial JNK/Sab/Src/ROS pathway in the mitochondria of H9c2 cells following H/R. (a) p-JNK, Sab, p-Src, c-Src, and COX-IV levels were detected by Western blot; n = 3. Data are expressed as the base of the levels of the H/R group. (b) The effect of F₂ on mitochondrial ROS generation was detected by the laser scanning confocal microscope; n = 3. Data are expressed as the base of the levels of the control group. (c) Colocalization of p-JNK and Sab in H9c2 cells was observed by the laser scanning confocal microscope. All values are expressed as means ± SEMs. *P < 0.05 vs. control group; **P < 0.05 vs. H/R group; ***P < 0.05 vs. H/R+F₂ group (×400, bar = 20 μm).
In comparison with the control group, the treatment of H/R and PP2 decreased MnSOD activity. In contrast, using SP600125, Sab siRNA, or F2 could reverse H/R-induced lower MnSOD activity (Table 2).

### 3.6.3. Mitochondrial Nonyl Acridine Orange Content

To further confirm the degree of mitochondrial oxidative stress damage, NAO fluorescence dye was used to evaluate the oxidative damage of the mitochondrial cardiolipin membrane. As shown in Figure 8, the treatment of SP600125, efficient knockdown of Sab, and use of F2 improved the H/R-induced oxidative damage of cardiolipin membrane, whereas inhibiting Src phosphorylation by PP2 triggered mitochondrial oxidative stress.

### 4. Discussion

Mitochondria in cardiomyocytes contribute to but in reverse suffer from oxidative stress injury. Damaged mitochondria not only cannot provide enough energy to the myocardium but also initiate additional myocardial I/R damage through other mechanisms, such as inducing apoptosis by releasing cytochrome C and an apoptosis-inducing factor [27–29], influencing the calcium balance of cardiomyocytes, disrupting the many signal chains of calcium ion downstream, and ultimately causing myocardial contractility dysfunction. The results of our laboratory study on primary cardiomyocytes or H9c2 cells showed that H/R causes mitochondrial swelling and crest reduction or disappearance and cellular apoptosis [20]. The above findings confirmed that H/R can cause mitochondrial damage and can cause whole-cell damage. In the present study, our results showed that the H/R stimulates mitochondrial ROS generation. At the same time, mitochondrial membrane potential, NAO levels, and MnSOD levels were also used to reflect mitochondrial damage, cardiolipin membrane oxidation, and mitochondrial SOD-scavenging ability, respectively. The results also showed that mitochondrial membrane potential, MnSOD activity, and NAO levels decreased after H/R in H9c2 cells, indicating that there were too many ROS produced in the mitochondria to clear, which resulted in oxidation of the cardiolipin membrane and subsequent mitochondrial oxidative stress injury. This injury initiated the prelude to comprehensive myocardial I/R injury.

JNK is a member of the MAPK family, which modulates various cellular functions, including proliferation, differentiation, and cell apoptosis [30]. Research on H/R or I/R models in the myocardium [31], renal cells [32], and the brain [33] showed that activated JNK mediates injury and that inhibition of p-JNK expression can reduce H/R- or I/R-induced apoptosis, death, or necrosis. Previous studies in our laboratory also indicated that the inhibition of JNK activation can improve the survival of cardiac microvascular endothelial cells [5], which were supported by the results of Li et al. [31] and Sun et al. [34]. Our present study also found that the JNK inhibitor SP600125 improves H/R-induced H9c2 cell viability (data not shown), suggesting that p-JNK is an injury factor in this experimental pathology model. In comparison with the control group, JNK activities were significantly higher in the cytoplasm of the H9c2 cells of each H/R group. Although the expression of p-JNK decreased slightly after H: 6 hours/R: 1 hour, it is still at a very high level in comparison with the control group. This trend of variation is similar to the results of Chambers et al. [17] obtained using a rat myocardial I/R model, which suggests that the model of H9c2 cell H/R injury established by the hypoxic/anaerobic

---

**Table 2:** Effects of F2 and inhibitors of the JNK/Sab/Src signal pathway on the change of MnSOD activity stimulated by H/R in H9c2 cells (mean ± SEM, n = 6).

| Group                  | MnSOD (U/mg prot) |
|------------------------|-------------------|
| Control                | 8.795 ± 0.7465    |
| H/R                   | 2.003 ± 0.5865*   |
| H/R+SP600125          | 8.096 ± 0.7342#   |
| H/R+NC siRNA          | 0.2478 ± 1.386*   |
| H/R+Sab siRNA         | 7.443 ± 2.262#    |
| Control+PP2            | 2.149 ± 0.7925*   |
| H/R+F2                | 8.701 ± 0.7400#   |

*P < 0.05 vs. control group; #P < 0.05 vs. H/R group.
workstation is very similar to the in vivo model of myocardial I/R injury.

Recently, Win et al. [16] proposed that cytoplasmic p-JNK can bind to the mitochondrial outer membrane Sab protein, resulting in mitochondrial Src inactivation and further inhibiting the electron transfer chain, which increases mitochondrial ROS generation and causes liver damage. A study involving an H2O2/FeSO4-induced H9c2 cell oxidative stress injury model showed translocation of p-JNK into the mitochondria and Sab binding, causing cell damage. When p-JNK translocation to the mitochondria was inhibited or its binding to the Sab protein was blocked, there was less cell damage [17]. Wiltshire et al. [35] first reported that p-JNK could bind to the Sab protein in the mitochondria, which provided the theoretical bases for the effect of p-JNK on mitochondria. In addition, a study has suggested that Src is necessary to maintain respiratory chain activity [36]. Ge et al. [15] found that the mitochondrial Src activated by ischemic preconditioning could regulate the activity of complex I and the level of mitochondrial ROS to antagonize myocardial I/R injury. It has not yet been elucidated whether abundantly activated JNK in the cytoplasm will translocate...
to mitochondria and what the relationship is between p-JNK and Sab, Src, and ROS in the mitochondria during myocardial I/R. Our results showed that, in H9c2 cells, H/R stimulated mitochondrial p-JNK expression and Src dephosphorylation but had no effect on the expression of Sab protein. In order to verify the existence of the interaction between p-JNK and Sab in H9c2 cells, an immunofluorescence colocalization technique was used to identify the p-JNK and Sab proteins. The results showed that the overexpression of p-JNK caused by H/R significantly increased the possibility of interaction with Sab protein in mitochondria, and Western blot results also showed that Sab siRNA significantly reduced the amount of p-JNK localized in the mitochondria. Taken together, the above results indicate that the mitochondrial translocation of cytoplasmic p-JNK is mediated by the anchoring protein Sab on the mitochondrial membrane during H/R stimulation of H9c2 cells. The results also showed that inhibiting the expression of p-JNK in mitochondria reduced the degree of dephosphorylation of Src, decreased the production of ROS in the mitochondria, and mitigated oxidative stress in the mitochondria, as evidenced by the increase in MnSOD activity, NAO levels, and mitochondrial membrane potential. While inhibiting Src phosphorylation that resulted in rapid generation of ROS in the mitochondria, a decrease in MnSOD activity, NAO levels, and mitochondrial membrane potential also occurred. These results support the hypothesis that there is a JNK/Sab/Src/ROS signal pathway in the mitochondria of H9c2 cells under H/R, which is closely related to mitochondrial oxidative stress injury. Inhibition of this pathway during H/R could reduce mitochondrial oxidative stress damage. Our previous study showed that ROS production during the process of H/R could increase the activation of cytoplasmic JNK [12], indicating that ROS can regulate the activation of cytoplasmic JNK during H/R. This study showed that inhibition of JNK activation in the cytoplasm will reduce mitochondrial translocation of p-JNK and ultimately lower ROS production in the mitochondria. Our results are in agreement with the study of Chambers et al., who found that H2O2/FeSO4-stimulated H9c2 cells increase the expression of p-JNK and induce ROS accumulation in the mitochondria [37]. On the basis of our results in combination with the literature, we propose that there is an ROS-induced ROS release loop in the myocardium following I/R—that is, an ROS/JNK/ROS loop mediated by Sab and Src proteins.

In our previous research, we also found that F2 could improve mitochondrial swelling and crest reduction or disappearance induced by H/R, mitigate mitochondrial damage, and antagonize the increase of cleaved caspase-3 induced by H/R, as well as inhibit the release of cytochrome C from the mitochondria [20] and apoptosis [38]. In addition, F2 inhibits I/R- or H/R-induced MDA production, an important index of ROS-induced lipid peroxidation, in the whole heart [39], cardiac-derived cardiomyocytes [6], and cardiac-derived microvascular endothelial cells [40]. At the same time, it exhibits an inhibitory effect on ROS-induced cardiac I/R- or H/R-associated inflammation as evidenced by the amelioration of Egr-1 overexpression. Therefore, F2 has a multiprotective effect on myocardial I/R injury. Via in-depth study on the mechanism of F2, we observed that it can regulate the abnormal ROS/JNK signaling pathway in the cardiomyocytes experiencing H/R and cardiac microvascular endothelial cells and antagonize whole-cell oxidative stress injury, including cell lipid membrane oxidation and cytosolic total SOD activity [5, 12]. In the present study, we further observed that F2 could inhibit the H/R-induced mitochondrial translocation of p-JNK and reduce the binding of p-JNK to the mitochondrial Sab protein, thereby inhibiting the dephosphorylation of Src by Sab protein and ROS generation, reducing mitochondrial oxidative stress, as demonstrated by the increasing MnSOD activity, NAO levels, and mitochondrial membrane potential. Altogether, this study demonstrated that F2 can reduce the damage associated with H/R-induced mitochondrial oxidative stress by modulating JNK/Sab/Src/ROS signaling pathways (Figure 9). At the same time, combined with previous research conducted by our group, we inferred that the effect of F2 on protecting cells from H/R-induced injury is related to adjusting the ROS/JNK/Sab/Src/ROS loop.

That being said, for now, we have no direct evidence that F2 derived from haloperidol still retains α1 adrenergic receptor blocking property, which results in its inhibition to ROS, but our previous studies suggest that myocardial I/R causes the decrease in systolic blood pressure (SP), diastolic blood pressure (DP), and mean arterial pressure (AP) in rats, respectively, whereas the administration of F2 reverses the decline of SP, DP, and AP induced by I/R [41], indicating F2 has no obvious effect to the α1 adrenergic receptor on peripheral vasodilation. Nevertheless, it is not clear whether F2 can block the α1 adrenergic receptor on the heart and thus affect ROS production, which will be the next interesting research direction.

**Figure 9:** Model of the JNK/Sab/Src/ROS signaling pathway and the role of F2 in H9c2 cells during H/R. H/R causes oxidative stress in mitochondria by activating JNK, which binds to mitochondrial outer membrane Sab protein, leading to inactivation of mitochondrial p-Src and increasing mitochondrial ROS production in H9c2 cells. F2 could inhibit H/R-induced JNK activation and ameliorate dephosphorylation of Src and reduce the mitochondrial ROS level.
5. Conclusions

In summary, H/R leads to the activation of a JNK/Sab/Src/ROS signaling pathway in the mitochondria of H9c2 cells, resulting in mitochondrial oxidative stress. F2 ameliorates H/R-induced mitochondrial oxidative stress through inhibiting the activation of the JNK/Sab/Src/ROS signaling pathway induced by H/R.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Authors’ Contributions

Qianwen Chu and Yanmei Zhang contributed equally to this work and should be considered co-first authors.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (no. 81773729, no. 81473215, and no. 81703508), the Natural Science Foundation of Guangdong Province of China (no. 2015A030313448), and the Guangdong Provincial Public Welfare Research and Capacity Building Special Fund Project (no. 2014A020212290). We are giving thanks to the Department of Education of Guangdong Province.

References

[1] T. Minamino, “Cardioprotection from ischemia/reperfusion injury: basic and translational research,” Circulation Journal, vol. 76, no. 5, pp. 1074–1082, 2012.
[2] J. R. Burgoyne, H. Mongue-Din, P. Eaton, and A. M. Shah, “Redox signaling in cardiac physiology and pathology,” Circulation Research, vol. 111, no. 8, pp. 1091–1106, 2012.
[3] L. Wu, J. L. Tan, Z. H. Wang et al., “ROS generated during early reperfusion contribute to intermittent hypobaric hypoxia-afforded cardioprotection against postschismic-induced Ca2+ overload and contractile dysfunction via the JAK2/STAT3 pathway,” Journal of Molecular and Cellular Cardiology, vol. 81, pp. 150–161, 2015.
[4] C. X. C. Santos, N. Anilkumar, M. Zhang, A. C. Brewer, and A. M. Shah, “Redox signaling in cardiac myocytes,” Free Radical Biology & Medicine, vol. 50, no. 7, pp. 777–793, 2011.
[5] S. Lu, Y. Zhang, S. Zhong et al., “N-n-butyl haloperidol iodide protects against hypoxia/reoxygenation injury in cardiac microvascular endothelial cells by regulating the ROS/MAPK/Egr-1 pathway,” Frontiers in Pharmacology, vol. 7, p. 520, 2017.
[6] Y. Zhang, G. Shi, J. Zheng et al., “The protective effects of N-n-butyl haloperidol iodide on myocardial ischemia-reperfusion injury in rats by inhibiting Egr-1 overexpression,” Cellular Physiology and Biochemistry, vol. 20, no. 5, pp. 639–648, 2007.
[7] M. Bliksøten, A. Baysa, L. Eide et al., “Mitochondrial DNA damage and repair during ischemia–reperfusion injury of the heart,” Journal of Molecular and Cellular Cardiology, vol. 78, pp. 9–22, 2015.
[8] K. Koga, A. Kenessey, S. R. Powell, C. P. Sison, E. J. Miller, and K. Ojamaa, “Macrophage migration inhibitory factor provides cardioprotection during ischemia/reperfusion by reducing oxidative stress,” Antioxidants & Redox Signaling, vol. 14, no. 7, pp. 1191–1202, 2011.
[9] W. Dong, R. Yang, J. Yang et al., “Resveratrol pretreatment protects rat hearts from ischemia/reperfusion injury partly via a NALP3 inflammasome pathway,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 8, pp. 8731–8741, 2015.
[10] K. Niizuma, H. Yoshioka, H. Chen et al., “Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1802, no. 1, pp. 92–99, 2010.
[11] H. M. Shen and Z. G. Liu, “JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species,” Free Radical Biology & Medicine, vol. 40, no. 6, pp. 928–939, 2006.
[12] Y. Zhang, H. Liao, S. Zhong et al., “Effect of N-n-butyl haloperidol iodide on ROS/JNK/Egr-1 signaling in H9c2 cells after hypoxia/reoxygenation,” Scientific Reports, vol. 5, no. 1, article 11809, 2015.
[13] M. Salvi, A. M. Brunati, L. Bordin, N. La Rocca, G. Clari, and A. Toninello, “Characterization and location of Src-dependent tyrosine phosphorylation in rat brain mitochondria,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1589, no. 2, pp. 181–195, 2002.
[14] T. Miyazaki, L. Neff, S. Tanaka, W. C. Horn, and R. Baron, “Regulation of cytochrome c oxidase activity by c-Src in osteoclasts,” Journal of Cell Biology, vol. 160, no. 5, pp. 709–718, 2003.
[15] H. Ge, M. Zhao, S. Lee, and Z. Xu, “Mitochondrial Src tyrosine kinase plays a role in the cardioprotective effect of ischemic preconditioning by modulating complex I activity and mitochondrial ROS generation,” Free Radical Research, vol. 49, no. 10, pp. 1210–1217, 2015.
[16] S. Win, T. A. Than, R. W. M. Min, M. Aghajan, and N. Kaplowitz, “c-Jun N-terminal kinase mediates mouse liver injury through a novel Sab (SH3BP5)-dependent pathway leading to inactivation of intramitochondrial Src,” Hepatology, vol. 63, no. 6, pp. 1987–2003, 2016.
[17] J. W. Chambers, A. Pachori, S. Howard, S. Iqbal, and P. V. LoGrasso, “Inhibition of JNK mitochondrial localization and signaling is protective against ischemia/reperfusion injury in rats,” Journal of Biological Chemistry, vol. 288, no. 6, pp. 4000–4011, 2013.
[18] F. F. Gao, S. Y. Hao, Z. Q. Huang et al., “Cardiac electrophysiological and antiarrhythmic effects of N-n-butyl haloperidol iodide,” Cellular Physiology and Biochemistry, vol. 25, no. 4–5, pp. 433–442, 2010.
[19] J. F. Xiao, C. Y. Wang, Y. P. Huang et al., “N-n-Butyl haloperidol iodide preserves cardiomyocyte calcium homeostasis during hypoxia/ischemia,” Cellular Physiology and Biochemistry, vol. 27, no. 5, pp. 433–442, 2011.
[20] B. Wang, S. Zhong, F. Zheng et al., “N-n-Butyl haloperidol iodide protects cardiomyocytes against hypoxia/reoxygenation injury by inhibiting autophagy,” Oncotarget, vol. 6, no. 28, pp. 24709–24721, 2015.
[21] T. Sun, Y. Zhang, S. Zhong et al., “N-n-Butyl haloperidol iodide, a derivative of the anti-psychotic haloperidol, antagonizes hypoxia/reoxygenation injury by inhibiting an Egr-1/ROS positive feedback loop in H9c2 cells,” *Frontiers in Pharmacology*, vol. 9, p. 19, 2018.

[22] J. Zhang, K. Ma, T. Qi et al., “P62 regulates resveratrol-mediated Fas/Cav-1 complex formation and transition from autophagy to apoptosis,” *Oncotarget*, vol. 6, no. 2, pp. 789–801, 2015.

[23] H. Wu, S. Liu, J. Gong et al., “VCPA, a novel synthetic derivative of α-tocopherol succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction,” *Cancer Letters*, vol. 393, pp. 22–32, 2017.

[24] P. Mukhopadhyay, M. Rajesh, G. Hasko, B. J. Hawkins, M. Madesh, and P. Pacher, “Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy,” *Nature Protocols*, vol. 2, no. 9, pp. 2295–2301, 2007.

[25] J. M. Petit, A. Mafthah, M. H. Rativaud, and R. Julien, “10N-Nonyl acridine orange interacts with cardiolipin and allows the quantification of this phospholipid in isolated mitochondria,” *European Journal of Biochemistry*, vol. 209, no. 1, pp. 267–273, 1992.

[26] J. Zhang, D. Wu, Z. Xing et al., “N-Isopropylacrylamide-modified polyethylenimine-mediated p53 gene delivery to prevent the proliferation of cancer cells,” *Colloids and Surfaces B: Biointerfaces*, vol. 129, pp. 54–62, 2015.

[27] C. M. Sag, S. Wagner, and L. S. Maier, “Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes,” *Free Radical Biology & Medicine*, vol. 63, pp. 338–349, 2013.

[28] C. Wang, N. Liu, R. Luan et al., “Apelin protects sarcomplasmic reticulum function and cardiac performance in ischaemia-reperfusion by attenuating oxidation of sarcomplasmic reticulum Ca2+-ATPase and ryanodine receptor,” *Cardiovascular Research*, vol. 100, no. 1, pp. 114–124, 2013.

[29] Y. Huang, F. Gao, Y. Zhang et al., “N-n-Butyl haloperidol iodide inhibits the augmented Na+/Ca2+ exchanger currents and L-type Ca2+ current induced by hypoxia/reoxygenation or H2O2 in cardiomyocytes,” *Biochemical and Biophysical Research Communications*, vol. 421, no. 1, pp. 86–90, 2012.

[30] C. R. Weston and R. J. Davis, “The JNK signal transduction pathway,” *Current Opinion in Genetics & Development*, vol. 12, no. 1, pp. 14–21, 2002.

[31] C. Li, C. Zhang, T. Wang, J. Xuan, C. Su, and Y. Wang, “Heme oxygenase 1 induction protects myocardial cells against hypoxia/reoxygenation-induced apoptosis: the role of JNK/c-Jun/caspase-3 inhibition and Akt signaling enhancement,” *Herz*, vol. 41, no. 8, pp. 715–724, 2016.

[32] Z. Yang, Z. Zhong, M. Li et al., “Hypothermic machine perfusion increases A20 expression which protects renal cells against ischemia/reperfusion injury by suppressing inflammation, apoptosis and necroptosis,” *International Journal of Molecular Medicine*, vol. 38, no. 1, pp. 161–171, 2016.

[33] L. Zhao, X. Chen, Q. Dai et al., “Role of FOXO3a in process of hydrogen-rich saline attenuating global cerebral ischemia-reperfusion injury in rats,” *Zhonghua Yi Xue Za Zhi*, vol. 95, no. 6, pp. 457–461, 2015.

[34] L. Sun, H. Fan, L. Yang, L. Shi, and Y. Liu, “Tyrosol prevents ischemia/reperfusion-induced cardiac injury in H9c2 cells: involvement of ROS, Hsp70, JNK and ERK, and apoptosis,” *Molecules*, vol. 20, no. 3, pp. 3758–3775, 2015.

[35] C. Wiltshire, M. Matsushita, S. Tsukada, D. A. F. Gillespie, and G. H. W. May, “A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria,” *Biochemical Journal*, vol. 367, no. 3, pp. 577–585, 2002.

[36] E. Tibaldi, A. M. Brunati, M. L. Massimino et al., “Src-tyrosine kinases are major agents in mitochondrial tyrosine phosphorylation,” *Journal of Cellular Biochemistry*, vol. 104, no. 3, pp. 840–849, 2008.

[37] J. W. Chambers and P. V. LoGrasso, “Mitochondrial c-Jun N-terminal kinase (JNK) signaling initiates physiological changes resulting in amplification of reactive oxygen species generation,” *Journal of Biological Chemistry*, vol. 286, no. 18, pp. 16052–16062, 2011.

[38] J. Z. Wang, C. Y. Cai, Y. M. Zhang et al., “N-n-Butyl haloperidol iodide protects against hypoxia/reoxygenation-induced cardiomyocyte injury by modulating protein kinase C activity,” *Biochemical Pharmacology*, vol. 79, no. 10, pp. 1428–1436, 2010.

[39] Z. Q. Huang, G. G. Shi, J. H. Zheng, and B. Liu, “Effects of N-n-butyl haloperidol iodide on rat myocardial ischemia and reperfusion injury and L-type calcium current,” *Acta Pharmacologica Sinica*, vol. 24, no. 8, pp. 757–763, 2003.

[40] Y. Zhou, Y. Zhang, F. Gao et al., “N-n-Butyl haloperidol iodide protects cardiac microvascular endothelial cells from hypoxia/reoxygenation injury by down-regulating Egr-1 expression,” *Cellular Physiology and Biochemistry*, vol. 26, no. 6, pp. 839–848, 2010.

[41] Y. Q. Zhou, G. G. Shi, F. F. Gao et al., “Effects of N-n-butyl haloperidol iodide on the hemodynamics of myocardial ischemia-reperfusion injury in rats,” *Chinese Pharmacological Bulletin*, vol. 20, no. 4, pp. 449–452, 2004.